Ipsen Licenses New Gout Drug to Menarini in €132M Deal

No Abstract

Ipsen SA has licensed rights to gout drug Adenuric - the first gout drug approved in four decades - in 41 countries to the Menarini Group in a deal that gives Ipsen €132 million (US$197 million).

Paris-based Ipsen will received €20 million up front, and retains co-marketing rights in France, where the companies will split market costs and profits, plus royalties in the low-teens on Menarini's net sales.